Spots Global Cancer Trial Database for gall bladder carcinoma
Every month we try and update this database with for gall bladder carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION | NCT05320328 | Bile Duct Neopl... Gall Bladder Ca... | Radio frequency... | 18 Years - 75 Years | Asian Institute of Gastroenterology, India | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Precise Treatment System of Biliary Malignancies Based on Special Disease Database | NCT03499782 | Cholangiocarcin... Gall Bladder Ca... Biliary System ... | 18 Years - 80 Years | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | ||
| Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection | NCT03779035 | Cholangiocarcin... Gall Bladder Ca... | Gemcitabine Capecitabine | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | NCT05712356 | Cholangiocarcin... Gallbladder Can... Gallbladder Car... Intrahepatic Ch... Extrahepatic Ch... Bile Duct Cance... Gall Bladder Ca... Gall Bladder Ca... | LSTA1 Durvalumab Cisplatin Gemcitabine FOLFOX regimen Placebo | 18 Years - | Lisata Therapeutics, Inc. | |
| A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | NCT03027284 | Advanced Cancer Metastatic Canc... Biliary Tract C... Cholangiocarcin... Gall Bladder Ca... Solid Tumor Non-Hodgkin's L... | Merestinib Cisplatin Gemcitabine | 20 Years - | Eli Lilly and Company | |
| Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | NCT02631590 | Biliary Carcino... Gall Bladder Ca... Cholangiocarcin... Gastrointestina... | Cisplatin Gemcitabine Copanlisib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection | NCT03779035 | Cholangiocarcin... Gall Bladder Ca... | Gemcitabine Capecitabine | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
